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Purpose: We evaluated the long-term effects of loxoprofen on nocturia in patients with 
benign prostatic hyperplasia (BPH).
Materials and Methods: Between January 2006 and December 2008, 40 BPH patients 
with 2 or more episodes of nocturia received an alpha-blocker, 5-alpha reductase in-
hibitor, and a single dose of 60 mg of loxoprofen at night before sleep for 12 months 
(Group I). During the same period, 38 BPH patients selected as the control group re-
ceived an alpha-blocker and 5-alpha reductase inhibitor (Group II). Patients were 
reevaluated after 3, 6, and 12 months of treatment by the number of nocturia episodes 
and side effects.
Results: After 3 months of treatment, the number of nocturia episodes decreased sig-
nificantly compared with baseline in both group I and group II (1.9±0.7, 2.1±0.7, re-
spectively, p＜0.05). The degree of decrease in nocturia was significantly different be-
tween the groups (−1.5±0.9, −1.1±0.9, respectively, p=0.034). After 6 and 12 months, 
the number of nocturia episodes decreased significantly compared with baseline in both 
group I and group II (p＜0.05), but the degree of decrease was not significantly different 
between the groups (p＞0.05). After 6 and 12 months of treatment in group I, treat-
ment-emergent adverse events, including 5 cases of gastric discomfort (12.5%), 3 cases 
of leg edema (7.5%), and 1 case of decreased urine volume (2.5%), occurred in 9 of the 
40 (22.5%) patients.
Conclusions: Loxoprofen can be an effective treatment for patients with nocturia secon-
dary to BPH in the short term. Long-term use of loxoprofen is not recommended because 
of the side effects.
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INTRODUCTION
Nocturia in patients with benign prostatic hyperplasia (BPH) 
is one of the most uncomfortable symptoms of the disease. 
It greatly affects quality of life by deteriorating the quality 
of sleep and disturbing activities during the day [1,2].
　Nocturia is relieved in only 25% to 39% of BPH patients 
treated with an alpha-blocker or 5-alpha reductase inhi-
bitor (5ARI), and nocturia of at least two times persists in 
38% of patients who undergo transurethral resection of the 
prostate [3-5]. In addition, using drugs such as anticholi-
nergics, hypnotics, or antidiuretics in combination with the 
above-mentioned therapies in order to reduce nocturia is 
not effective in many cases.
　Loxoprofen sodium (loxoprofen), a nonsteroidal anti-in-
flammatory drug (NSAID), is a nonselective cyclooxygenase 
(COX) inhibitor. There are reports indicating that short- 
term use of loxoprofen can reduce the number of episodes 
of nocturia [6-11]. 
　However, no studies have assessed the long-term effects 
of loxoprofen on nocturia. We thus conducted a retrospec-
tive study to assess the effect of long-term use of loxoprofen 
on nocturia in patients with BPH.Korean J Urol 2011;52:265-268
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TABLE 1. Baseline characteristics
Loxoprofen 
group
Control 
group
p-value
Age (yr) 69.8±6.9  63.3±6.9  0.790
PSA (ng/ml) 2.7±2.9 2.3±1.9 0.139
Prostate volume (ml) 47.1±13.9 53.3±15.8 0.429
IPSS
　Total 24.9±5.0  22.7±5.0  0.895
　Storage 10.3±2.0 9.6±2.1 0.592
　Voiding 14.5±4.1  13.1±3.7  0.434
　No. of nocturia 3.5±0.8 3.3±0.8 0.787
　QoL 4.3±0.8 4.0±0.9 0.570
PSA: prostate-specific antigen, IPSS: International Prostate 
Symptom Score, QoL: quality of life
TABLE 2. Mean changes in the number of episodes of nocturia com-
pared with baseline 
Changes in nocturia number 
compared with baseline
p-value
a
Loxoprofen 
group
Control 
group
After 3 mo
After 6 mo
After 12 mo
−1.5±0.9 
(p＜0.001)
b
−1.3±0.9
(p＜0.001)
b
−1.1±1.1
(p＜0.001)
b
−1.1±0.9
(p＜0.001)
b
−1.2±1.0
(p＜0.001)
b
−1.2±1.3
(p＜0.001)
b
0.034
0.794
0.759
a: statistical significance between groups, 
b: p＜0.05 vs. baseline
FIG. 1. Degree of decrease in the number of episodes of nocturia
compared with baseline after 3, 6, and 12 months of treatment in
both groups. 
a: statistical significance between groups.
MATERIALS AND METHODS
The hospital records of patients with BPH who visited our 
hospital for lower urinary tract symptoms (LUTS) from 
January 2008 to December 2008 were analyzed retro-
spectively. Among them, we chose patients who complained 
of continued nocturia of two times or more even after the 
use of an alpha-blocker and 5ARI for 3 months or longer. 
Among the patients who were able to be followed up for 12 
months, 40 patients received an alpha-blocker and 5ARI 
as well as loxoprofen 60 mg before sleep (loxoprofen group) 
and 38 patients received only an alpha-blocker and 5ARI 
(control group). We compared the number of nocturia epi-
sodes in the two groups before loxoprofen administration 
and the number of episodes of nocturia and the Interna-
tional Prostate Symptom Score (IPSS) after treatment for 
3, 6, and 12 months. Adverse events were also examined 
for each period.
　We excluded patients who had a history of undergoing 
treatment or operation for BPH, acute urinary retention, 
urinary tract infection, bladder stone, urethral stricture, 
or neurogenic bladder as well as patients who had taken 
or were taking drugs such as anticholinergics, cholinergics, 
or diuretics that can affect voiding symptoms.
　Differences in the number of episodes of nocturia by peri-
od between the two groups were analyzed by unpaired 
t-tests, and differences between before and after treatment 
in each group were analyzed by paired t-tests. The results 
were judged to be statistically significant when the p-value 
was smaller than 0.05. The statistics program used in this 
study was SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
There were no significant differences between the two groups 
at the time of loxoprofen administration in age, prostate- 
specific antigen (PSA), prostate volume, IPSS, or number 
of episodes of nocturia (Table 1).
　The number of episodes of nocturia in the two groups at 
3 months after treatment was 1.9±0.7 and 2.1±0.7, respec-
tively, and thus was significantly reduced after treatment 
in both groups (p＜0.05). The degree of reduction in noctu-
ria in the two groups was −1.5±0.9 times and −1.1±0.9 
times, respectively. Thus, the number of episodes was re-
duced more in the loxoprofen group (p=0.034). The number 
of episodes of nocturia in the two groups at 6 and 12 months 
after treatment was significantly reduced compared with 
before treatment (p＜0.05), but there was no significant 
difference in the degree of reduction between the two 
groups (p＞0.05) (Table 2, Fig. 1).
　The adverse events found in the loxoprofen group were 
gastric discomfort in four patients (10.0%) and decreased 
urine output in one patient (2.5%) at 6 months after treat-
ment and gastric discomfort in one patient (2.5%) and lower 
leg edema in three patients (7.5%) at 12 months after treat-
ment. In the control group, on the other hand, gastric dis-
comfort was found in one patient (2.6%) at 3 months after 
treatment, and gastric discomfort occurred in one patient 
(2.6%) and lower leg edema in one patient (2.6%) at 6 months 
after treatment (Table 3).Korean J Urol 2011;52:265-268
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TABLE 3. Adverse events following treatment 
Adverse events
No. of patients (%)
Loxoprofen group (n=40) Control group (n=38)
3 mo 6 mo 12 mo 3 mo 6 mo 12 mo
Gastric discomfort 0 (0) 4 (10.0) 1 (2.5) 1 (2.6) 1 (2.6) 0 (0)
Leg edema 0 (0) 0 (0) 3 (7.5) 0 (0) 1 (2.6) 0 (0)
Decrease in urine volume 0 (0) 1 (2.5) 0 (0) 0 (0) 0 (0) 0 (0)
Cardiovascular event 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
DISCUSSION
Although the most frequent cause of LUTS in males is lower 
urinary tract obstruction by BPH, in addition to the ob-
struction, many factors such as dysfunctional detrusor, 
sensory disturbance, and polyuria work as mechanisms of 
LUTS [12]. 
　Combination therapy (alpha-blocker＋5ARI) is widely 
used as a drug treatment for LUTS in BPH patients. If noc-
turia persists even with combination therapy, however, 
other drugs such as anticholinergics, antidiuretics, and 
hypnotics are often added.
　Loxoprofen, an NSAID, is a nonselective COX inhibitor 
that suppresses prostaglandin (PG) synthesis [6,7]. PGs 
are formed in the lower urinary tract and show diverse ef-
fects on the kidney, the bladder, the ureter, and the sym-
pathetic nerve system. Among the many PGs, prosta-
glandin E (PGE) and prostaglandin F (PGF) are known to 
increase the contractility of the detrusor [13,14].
　Loxoprofen’s effect on LUTS can be considered to have 
four different mechanisms. First, loxoprofen reduces blood 
flow from the kidney to the glomeruli, thereby reducing 
urine production [15]. Second, it suppresses PGF, which re-
duces the detrusor’s contractility, thereby reducing the de-
sire to void [16,17]. Third, it suppresses afferent or efferent 
nerve pathways to raise the threshold of the sense of uri-
nation of the central nervous system [18,19]. Last, it affects 
the sleep cycle of the brain to induce sufficient sleep [20,21]. 
　In a study of loxoprofen and nocturia, Okada et al reported 
that nocturia was reduced by approximately 1.6 times when 
loxoprofen was taken before sleep for 2 weeks [8]. Saito et 
al had patients take loxoprofen before sleep for 1 week and 
reported the improvement of nocturia by approximately 
two times [9]. Chang et al reported that when loxoprofen 
had been administered before sleep for 2 weeks to nocturia 
patients who had not shown any effect of anticholinergics 
and hypnotics, the number of nocturia episodes was re-
duced in approximately 74.7% of the patients [10]. Araki 
et al reported that in the case of BPH patients who had not 
shown any effect of anticholinergics, hypnotics, tricyclic 
antidepressants, or antidiuretic hormone, the number of 
nocturia episodes was reduced in approximately 74.2% 
when loxoprofen was administered before sleep for 2 weeks 
[11]. However, none of these studies were conducted for lon-
ger than 2 weeks, and until now no study had been con-
ducted on changes in nocturia after the administration of 
loxoprofen for 1 month or longer. In the present study, BPH 
patients with refractory nocturia with no past history of use 
of other drugs were followed up for a long period of time of 
12 months with the administration of an alpha-blocker, 
5ARI, and loxoprofen 60 mg one time before sleep every day. 
Our results suggest that the number of episodes of nocturia 
was reduced more in the loxoprofen group than in the con-
trol group. This study can be said to be quite meaningful 
because it is the first study to evaluate the long-term effect 
of loxoprofen on nocturia.
　However, although the number of nocturia episodes de-
creased more in the loxoprofen group than in the control 
group at 3 months after loxoprofen administration, the de-
crease in the number of nocturia episodes became similar 
between the two groups after 6 months. This may be be-
cause the long-term use of 5ARI reduced the volume of the 
prostate, thereby improving the LUTS and affecting the 
number of episodes of nocturia. It is also assumed that the 
effect of loxoprofen might have been reduced after 3 months 
in the loxoprofen group. More studies should be performed 
to understand the mechanism and causes of the reduced 
effect of loxoprofen after its long-term use. 
　In a study of adverse events resulting from loxoprofen, 
Waikakul and Waikakul reported that adverse events oc-
curred in 8.4% of 1,206 patients aged 56 years on average 
[22]. Among the adverse events, gastric discomfort occurred 
the most frequently. In our study, no adverse event ap-
peared until 3 months after the administration of loxopro-
fen. When loxoprofen had been administered for longer 
than 6 months, six cases of gastric discomfort (12.5%), three 
cases of leg edema (7.5%), and one case of decreased urine 
volume (2.5%) were noted. But, all of these complications 
were mild and did not indicate a necessity to stop the admi-
nistration of loxoprofen. However, because the long-term 
use of loxoprofen in older people may involve relatively 
high risks of side effects such as gastric discomfort and re-
nal failure, and because these adverse events in older peo-
ple may be fatal, long-term use of loxoprofen should be con-
sidered carefully. 
　The present study was conducted on patients who had 
not used drugs such as anticholinergics, hypnotics, and an-
tidiuretics that are commonly used in the treatment of 
nocturia. By excluding drugs commonly used in the treat-
ment of nocturia and using loxoprofen for 3 months, we Korean J Urol 2011;52:265-268
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could show that loxoprofen was helpful in the rapid im-
provement of nocturia. However, this was a retrospective 
study in a small number of patients. Therefore, prospective 
research on a larger scale is necessary to prove the exact 
effect of loxoprofen on nocturia. Furthermore, additional 
research on the extent of reduction in nocturia and whether 
patients’ quality of life is improved by the administration 
of the drug should be performed. 
CONCLUSIONS
We evaluated the long-term effect of loxoprofen on nocturia 
for the first time. Among BPH patients with refractory noc-
turia, the number of nocturia episodes was reduced more 
in the loxoprofen group than in the control group after 3 
months of loxoprofen treatment. Loxoprofen can be consid-
ered as one of the treatment options for rapid improvement 
in nocturia in BPH patients. It is recommended that lox-
oprofen be used for short periods of time in older patients 
considering the side-effects of long-term use of loxoprofen. 
Because our study was conducted on a small number of pa-
tients, the long-term effects and side-effects of loxoprofen 
should be studied further through large-scale studies on 
larger numbers of patients.
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